Arthritis Research Education Series Ep. 11 - Biosimilars Unpacked
In 2019, British Columbia announced its biosimilars initiative. Since then, other provinces and territories have followed suit. This means people on biologic originators, for which there are biosimilars, will be (or have already) transitioned to biosimilars in these provinces. Individuals starting a drug for the first time will be prescribed a biosimilar rather than a biologic.
Biosimilars are safe, effective, near-identical copies of their biologic originators and are held to the same rigorous standards. However, any treatment changes can be concerning – especially once someone has found a medication that works for them.
We’re conducting research to understand the impact of biosimilar transition policies on people living with different types of inflammatory arthritis.
Discover biosimilars research, resources, patient stories and more in Episode 11 of the Arthritis Research Education Series: https://bit.ly/3szxhcj
#ArthritisResearch